Paolo Tarantino
“Two weeks to ESMO 2024.
Multiple important breast oncology trials to be presented at the conference, including phase 3 readouts, updates of key practice-changing trials and phase 1 trials of novel ADCs, IO and targeted drugs.
Here’s a personal, non-exhaustive selection of 10 breast cancer abstracts not to miss at ESMO24.
See you in Barcelona!”
Source: Paolo Tarantino/LinkedIn
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.